“The issuer has good patient volumes and cost efficiency and its financial profile also shows an increasing trend. The issue is fairly priced at a P/E (price to earnings ratio) of 43 compared to the average industry P/E of 51.93,” said Parth Nyati, who had recommended the Medanta IPO only for long-term investors.